Occipital Nerve Stimulation for Pain Modulation in Drug-Resistant Chronic Cluster Headache

Occipital nerve stimulation (ONS) is a surgical treatment proposed for drug-resistant chronic cluster headache (drCCH). Long-term series assessing its efficacy are scarce. We designed a retrospective observational study with consecutive sampling, evaluating the follow-up of 17 drCCH patients who und...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain sciences 2021-02, Vol.11 (2), p.236
Hauptverfasser: Díaz-de-Terán, Javier, Membrilla, Javier A, Paz-Solís, José, de Lorenzo, Iñigo, Roa, Javier, Lara-Lara, Manuel, Gil-Martínez, Alfonso, Díez-Tejedor, Exuperio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Occipital nerve stimulation (ONS) is a surgical treatment proposed for drug-resistant chronic cluster headache (drCCH). Long-term series assessing its efficacy are scarce. We designed a retrospective observational study with consecutive sampling, evaluating the follow-up of 17 drCCH patients who underwent ONS. Our main endpoint was the reduction the rate of attacks per week. We also evaluated the pain intensity through the Visual Analogue Scale (VAS), patient overall perceived improvement and decrease in oral medication intake. After a median follow-up of 6.0 years (4.5-9.0), patients decreased from a median of 30 weekly attacks to 22.5 (5.6-37.5, = 0.012), 7.5 at 1 year ( = 0.006) and 15.0 at the end of follow-up ( = 0.041). The VAS decreased from a median of 10.0 to 8.0 ( = 0.011) at three months, to 7.0 ( = 0.008) at twelve months and 7.0 ( = 0.003) at the end of the follow-up. A total of 23.5% had an overall perceived improvement of ≥70% at 3 months, 41.2% at 1 year and 27.8% at the end of follow-up. Reducing prophylactic oral medication was possible in 76.5% and it was stopped in 17.7%. Triptan use decreased in all the responder patients and 17.7% stopped its intake. A total of 41.2% presented mild adverse events. In conclusion, our long-term experience suggests that ONS could be an interesting option for drCCH-selected patients, as it is a beneficial and minimally invasive procedure with no serious adverse events.
ISSN:2076-3425
2076-3425
DOI:10.3390/brainsci11020236